glp 1 cardiovascular benefits GLP-1 receptor agonists and outcome trials: An update Cardiovascular Effects of Glucagon-Like Peptide-1

December 2025: Growing integration of GLP-1 therapies in Japan's diabetes clinics and hospitals, driven by increasing obesity-related comorbidities and demand for convenient administration routes

Today, the majority of the emerging GIP receptor targeting compounds are claimed to be agonists, and to increase insulin secretion (91), and also, suppress appetite (119)

10.1210/endo.141.11.7752 91 HeY.LuY.RenW.ShenJ.WuK.XuK.et al (2019)

91 In UC patients, endoplasmic reticulum function may be impaired, leading to abnormal accumulation of intracellular proteins and exacerbation of the cellular inflammatory response

Widely used weight-loss and diabetes drugs show clear benefits, but emerging evidence clarifies their side effects, rare risks, and what clinicians should monitor long term

Personalized Medication Options Some patients may be better candidates for Semaglutide, while others may discuss Tirzepatide, oral GLP-1 drops, microdosing, or maintenance support